Bone regeneration from frozen marrow mesenchymal cells/recombinant human bone morphogenetic protein/hydroxyapatite transplantation

被引:0
|
作者
Miyazaki, K [1 ]
Yoshikawa, T
Iida, J
Ueda, Y
Koizumi, M
Sato, N
Shigematu, H
Dohi, Y
Ohgushi, H
Takakura, Y
机构
[1] Nara Med Univ, Dept Orthopaed Surg, Kashihara, Nara 6348522, Japan
[2] Nara Med Univ, Dept Publ Hlth, Kashihara, Nara 6348522, Japan
[3] Natl Inst Adv Ind Sci & Technol, Res Inst Cell Engn, Amagasaki, Hyogo 6610974, Japan
来源
BIOCERAMICS 18, PTS 1 AND 2 | 2006年 / 309-311卷
关键词
mesenchymal stem cell; bone morphogenetic protein; hydroxyapatite;
D O I
10.4028/www.scientific.net/KEM.309-311.1009
中图分类号
TQ174 [陶瓷工业]; TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Introduction: Marrow mesenchymal cells contain stem cells and can regenerate tissues. We previously reported the clinical application of autologous cultured bone to regeneration therapy. However, in cases with low numbers of active cells, culture is often unsatisfactory. If frozen marrow cells retain their osteogenic potential, we could clinically use them in regeneration therapy as alternatives to high active cells obtained from youngsters. Here, we examined osteogenic potential of frozen human mesenchymal stem cells in combination with recombinant human bone morphogenetic protein (rhBMP) using biochemical and histological analyses. Method: Mar-row fluid was aspirated from the human iliac bone of a 46-year-old man with lumbar canal stenosis during surgery. Two weeks after primary culture in standard medium, bone marrow mescnchymal stem cells (BMSCs) were trypsinized for the preparation of a cell suspension, and cells were concentrated to 10(6) cells/ml by centrifugation. Cells were kept at -80 degrees C until use. To impregnate porous hydroxyapatite (HA) with rhBMP, 1 mu g rhBMP/20 mu l 0.1% trifluoroacetic acid was applied on HA, and then desiccated under vacuum. In the present study, we used 4 subgroups: BMSC/rhBMP/HA, BMSC/HA, rhBMP/HA, and HA only. HA constructs from the 4 subgroups were implanted at subcutaneous sites on the back of 5-week-old nude mice (BALB/cA Jcl-nu). Eight weeks after implantation, implanted HA constructs were harvested, and biochemical and histological analyses were performed. Alkaline phosphatase activity (ALP) and human osteocalcin (hOs) levels were measured. Results and Discussion: ALP activity and hOs in the BMSC/BMP/HA subgroup were 2 or 3 times that in the BMSC/HA subgroup. Histological analysis showed that significant bone formation was observed in these two subgroups, and supported biochemical data. However, in the BMP/HA and HA only subgroups, significant bone formation could not be detected histologically nor biochemically. These results indicated that a combination of rhBMP and BMSCs, and only with a minimal amount of 1 mu g rhBMP, allowed successful generation of human bone. In the human body, rhBMP in the order of milligrams is necessary for bone formation. However, by combining BMSCs, HA and rhBMP, only a small amount of rhBMP was needed to dramatically enhance osteogenic potential. As we reported here, cryopreserved BMSCs also showed high osteoblastic activity. In conclusion, this study provided histological and biochemical evidence that combination of cryopreserved BMSCs, BMP, and porous HA could enhance osteogenic potential.
引用
收藏
页码:1009 / 1012
页数:4
相关论文
共 50 条
  • [1] Experimental study on bone formation potential of cryopreserved human bone marrow mesenchymal cell/hydroxyapatite complex in the presence of recombinant human bone morphogenetic protein-2
    Shimakura, Y
    Yamzaki, Y
    Uchinuma, E
    JOURNAL OF CRANIOFACIAL SURGERY, 2003, 14 (01) : 108 - 116
  • [2] Periimplant bone regeneration in hydroxyapatite block grafts with mesenchymal stem cells and bone morphogenetic protein-2
    Park, Jee-Hyun
    Jung, Young-Eun
    Kim, Myung-Jin
    Hwang, Soon Jung
    TISSUE ENGINEERING AND REGENERATIVE MEDICINE, 2016, 13 (04) : 437 - 445
  • [3] Periimplant bone regeneration in hydroxyapatite block grafts with mesenchymal stem cells and bone morphogenetic protein-2
    Jee-Hyun Park
    Young-Eun Jung
    Myung-Jin Kim
    Soon Jung Hwang
    Tissue Engineering and Regenerative Medicine, 2016, 13 : 437 - 445
  • [4] Spatial Recombinant Human Bone Morphogenetic Protein 2 Delivery from Hydroxyapatite Scaffolds Sustains Bone Regeneration in Rabbit Radius
    Ong, Joo L.
    Shiels, Stefanie M.
    Pearson, Joseph
    Karajgar, Suyash
    Miar, Solaleh
    Chiou, Gennifer
    Appleford, Mark R.
    Wenke, Joseph C.
    Guda, Teja
    TISSUE ENGINEERING PART C-METHODS, 2022, 28 (07) : 363 - 374
  • [5] Bone morphogenetic protein-2 enhances bone regeneration mediated by transplantation of osteogenically undifferentiated bone marrow-derived mesenchymal stem cells
    Kang, Sun-Woong
    La, Wan-Geun
    Kang, Jin Muk
    Park, Jung-Ho
    Kim, Byung-Soo
    BIOTECHNOLOGY LETTERS, 2008, 30 (07) : 1163 - 1168
  • [6] Bone morphogenetic protein-2 enhances bone regeneration mediated by transplantation of osteogenically undifferentiated bone marrow-derived mesenchymal stem cells
    Sun-Woong Kang
    Wan-Geun La
    Jin Muk Kang
    Jung-Ho Park
    Byung-Soo Kim
    Biotechnology Letters, 2008, 30 : 1163 - 1168
  • [7] Recombinant human bone morphogenetic protein-2 and collagen for bone regeneration
    Hollinger, JO
    Schmitt, JM
    Buck, DC
    Shannon, R
    Joh, SP
    Zegzula, HD
    Wozney, J
    JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1998, 43 (04): : 356 - 364
  • [8] Bone regeneration with recombinant human bone morphogenetic protein 2: a systematic review
    de Queiroz Fernandes J.
    de Lima V.N.
    Bonardi J.P.
    Filho O.M.
    Queiroz S.B.F.
    Journal of Maxillofacial and Oral Surgery, 2018, 17 (1) : 13 - 18
  • [9] EFFICACY OF HYDROXYAPATITE CERAMIC AS A CARRIER FOR RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN
    ONO, I
    GUNJI, H
    KANEKO, F
    SAITO, T
    KUBOKI, Y
    JOURNAL OF CRANIOFACIAL SURGERY, 1995, 6 (03) : 238 - 244
  • [10] A new recombinant human bone morphogenetic protein-2 carrier for bone regeneration
    Yokota, S
    Sonohara, S
    Yoshida, M
    Murai, M
    Shimokawa, S
    Fujimoto, R
    Fukushima, S
    Kokubo, S
    Nozaki, K
    Takahashi, K
    Uchida, T
    Yokohama, S
    Sonobe, T
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 223 (1-2) : 69 - 79